


The logo for the Developmental Biology for Regenerative Medicine (DBRM) center, consisting of the lowercase letters 'dbrm' in a white, sans-serif font on a dark grey rectangular background.

THE  
HUMAN  
REGENERATIVE  
MAP

## Call for applications to the DBRM and THRM TReC research project grants 2010

### Background

DBRM (Developmental Biology for Regenerative Medicine, [www.dbrm.se](http://www.dbrm.se)) and THRM (The Human Regenerative Map, [www.thrm.ki.se](http://www.thrm.ki.se)) are two Linné centers, supported by the Swedish Research Council. The aim of DBRM is to conduct internationally leading research in stem cell biology, developmental biology and regenerative medicine. DBRM consists of 13 research groups, with expertise in basic science. THRM aims at establishing a map of cell turnover in the human body in health and disease. To accomplish this, THRM has devised a novel strategy based on the resetting of  $^{14}\text{C}$  in the atmosphere following nuclear bomb tests to retrospectively establish the birth date of cells.

Both DBRM and THRM have the mission to strengthen the links to clinical science at the Karolinska Institute (KI). To this end, DBRM and THRM have initiated a Translational Research Center (TReC), to facilitate the interactions between basic and clinical science. The Scientific Board at TReC consists of Drs. Ernest Arenas, Jonas Frisé, Katarina Le Blanc and Urban Lendahl. In addition to organizing courses, workshops and symposia to bring basic and clinical scientists at KI closer together, a mission for TReC is to provide funding for research projects spanning basic and clinical science.

### TReC Research Project grants

TReC will provide approximately 1000 kSEK funding annually to projects that have a combined basic and clinical aspect in the areas of stem cell biology, developmental biology or regenerative medicine. The underlying idea is to i) bring questions addressed in DBRM and THRM closer to the clinical setting, or conversely, ii) provide cell or molecular biology expertise to questions addressed in the clinic. The following guidelines apply for the project applications:

1. The application should be a joint application from a PI in DBRM or THRM and a scientist at KI outside DBRM and THRM, working on more clinically oriented problems. Applications should address important problems in stem cell biology, developmental biology or regenerative medicine.

2. It is preferable that the application has a sufficiently strong clinical component to also be in principal appropriate for funding through the ALF system (although there is no strict requirement for simultaneously applying for ALF grants). The rationale for this is to make the TReC projects distinct from already ongoing, more basic research-oriented, projects in DBRM and THRM.

3. The application should not exceed 3 A4 pages (single spacing, font 12, including references and figures). Applications should be sent in full, there is no pre-proposal procedure. Applications should be sent as single PDF files to [Ola.Hermanson@ki.se](mailto:Ola.Hermanson@ki.se). A one-page CV for each PI, including a list of five relevant publications, should also be enclosed. There is no requirement for a detailed budget, only for an estimate of how the funding will be distributed between the DBRM partner and the clinical scientist.

4. Applications will be judged for scientific merit by the TReC Scientific Board (see above), and if deemed necessary by the Board, for example because of conflicts of interest, by ad hoc outside experts.

5. We expect that up to five applications per year can be funded, which means that successful applications can be funded in the range of 200-300 kSEK/year. The funding period is one year, and the application should be written to reflect this time period.

The deadline for applications is **September 10, 2010**. Further information can be obtained from Ola Hermanson ([Ola.Hermanson@ki.se](mailto:Ola.Hermanson@ki.se)).